Pro-Dex (NASDAQ:PDEX – Get Free Report) released its quarterly earnings data on Thursday. The medical instruments supplier reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25, FiscalAI reports. The firm had revenue of $20.56 million for the quarter, compared to the consensus estimate of $20.40 million. Pro-Dex had a net margin of 17.62% and a return on equity of 25.13%.
Pro-Dex Stock Performance
PDEX traded down $1.59 during trading on Thursday, hitting $61.60. The stock had a trading volume of 43,096 shares, compared to its average volume of 51,161. The company has a 50 day moving average price of $65.04 and a 200-day moving average price of $56.30. The firm has a market cap of $199.15 million, a price-to-earnings ratio of 14.92 and a beta of 0.04. Pro-Dex has a one year low of $28.81 and a one year high of $77.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.10 and a quick ratio of 2.45.
Insider Buying and Selling at Pro-Dex
In other Pro-Dex news, CFO Alisha Charlton sold 2,300 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total transaction of $140,990.00. Following the transaction, the chief financial officer owned 21,870 shares in the company, valued at $1,340,631. This trade represents a 9.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of Pro-Dex stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $60.58, for a total value of $1,165,256.30. Following the sale, the chief executive officer directly owned 79,993 shares of the company’s stock, valued at $4,845,975.94. This represents a 19.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,300 shares of company stock worth $1,351,657 in the last quarter. Company insiders own 48.00% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Stock Analysis on Pro-Dex
About Pro-Dex
Pro-Dex, Inc (NASDAQ:PDEX) designs, develops and manufactures powered surgical instruments and related products for the medical device industry. The company primarily serves original equipment manufacturers that incorporate Pro-Dex instruments into surgical systems sold under their own brands.
Its products include battery-powered and pneumatic handpieces, rotary instruments, micro-drills, saws, controllers and other specialized equipment used in orthopedic, dental, ophthalmic and other surgical applications.
Further Reading
- Five stocks we like better than Pro-Dex
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
